MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
4.780
-0.220
-4.40%
Closed 19:41 12/17 EST
OPEN
5.00
PREV CLOSE
5.00
HIGH
5.04
LOW
4.740
VOLUME
4.47M
TURNOVER
0
52 WEEK HIGH
7.30
52 WEEK LOW
1.260
MARKET CAP
1.27B
P/E (TTM)
-4.9243
1D
5D
1M
3M
1Y
5Y
1D
ValuEngine Weekly Market Summary And Commentary
Seeking Alpha · 2d ago
Weekly Report: what happened at SANA last week (1208-1212)?
Weekly Report · 3d ago
Sana Biotechnology (SANA): Valuation Check After New In Vivo Gene Editing Data in Nature Biotechnology
Simply Wall St · 12/10 00:38
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/09 21:07
Sana Biotechnology announces publication of in vivo gene editing
TipRanks · 12/08 14:05
Sana Biotechnology Says Nature Biotechnology Publishes Journal Article Titled "In Vivo Gene Editing Of Human Hematopoietic Stem And Progenitor Cells Using Envelope-Engineered Virus-Like Particles"
Benzinga · 12/08 14:05
Sana Biotechnology Achieves Potent In Vivo Gene Editing of Human Stem Cells Using Fusogen Technology
Reuters · 12/08 14:00
Weekly Report: what happened at SANA last week (1201-1205)?
Weekly Report · 12/08 09:22
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.